Antidote Treatment Nerve Agent Auto-Injector (ATNAA)
Awarded Limited / Sole Source Justification Posted
Not the latest version. See the latest pre-solicitation from .
- Solicitation number
- SPE2DP-26-D-0001
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- SPE2DP-26-D-0001 Federal IDV award
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Philadelphia, Pennsylvania 19111, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical Supply Chain issued a Limited/Sole Source Justification Notice on December 10, 2025, for a contract award to Meridian Medical Technologies, LLC for the manufacture and delivery of the Antidote Treatment Nerve Agent Auto-Injector (ATNAA), a dual-chamber injector containing atropine and pralidoxime chloride used to treat organophosphorus nerve agent poisoning. The justification for sole source procurement is based on Meridian Medical Technologies being the only FDA-approved manufacturer of this specific auto-injector, a critical medical countermeasure exclusively supplied to the United States Military. The contract, designated SPE2DP-26-D-0001 and awarded on December 5, 2025, consists of a one-year base contract with four one-year option periods and encompasses a minimum quantity of 225,000 units and maximum quantity of 1,000,000 units per year. The specific contract award amount is redacted in the published notice, though the national stock number is identified as 6505-01-362-7427. Prior to this sole source award, the government conducted a Sources Sought Notice in June 2023 to identify alternative suppliers, which generated three responses but did not result in identification of competing qualified sources.
Notice text
In accordance with FAR 6.305(a), please see attachment for the redacted justification and approval for contract award to Meridian Medical Technologies, LLC for the manufacture and delivery of ATNAA.
Awarded contract SPE2DP-26-D-0001 to unknown vendor for unknown amount on 2025-12-05.
Files
| File | Type | Posted |
|---|---|---|
| 23R0002_ATNAA_JA_FINAL_Signed_Redacted1.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Atnaa | Pre-Solicitation | |
| This notice | Limited / Sole Source Justification | |
| Antidote Treatment Nerve Agent Auto-Injector (ATNAA) | Pre-Solicitation | |
| Antidote Treatment Nerve Agent Auto-Injector (ATNAA) | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Atropine Auto-Injector | Medical Supply Chain | No set-aside | |
| Epinephrine Injector | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity